Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity

Detalhes bibliográficos
Autor(a) principal: Pérez-Betancourt, Yunys Pérez
Data de Publicação: 2022
Tipo de documento: Tese
Idioma: eng
Título da fonte: Biblioteca Digital de Teses e Dissertações da USP
Texto Completo: https://www.teses.usp.br/teses/disponiveis/46/46131/tde-23052022-152413/
Resumo: Adjuvants activate innate immunity by diverse mechanisms simulating the activity of danger signals present in entire pathogens but absent in purified antigens used in vaccines. Cationic nanoparticles (NPs) are promising adjuvants as they may show high colloidal stability, they adsorb oppositely charged antigens, and they increase antigens uptake by antigen-presenting cells (APC). The high toxicity displayed by isolated cationic lipids or polymers has hampered their use in vaccines. In this work, the toxicity of cationic materials is overcome by combining them with biocompatible polymers. Herein is described the preparation, characterization, toxicity, and immunoadjuvant activity of three cationic NPs, poly(diallyldimethylammchloride)/ovalbumin (PDDA/OVA), poly(methyl methacrylate)/dimethyldioctadecylammonium bromide/PDDA (PMMA/DODAB/PDDA), and PMMA/DODAB. NPs of PDDA/OVA were prepared by mixing PDDA and OVA; NPs of PMMA/DODAB/PDDA and PMMA/DODAB NPs were synthesized by emulsion polymerization of methyl methacrylate (MMA) in the presence of cationic components. Dispersion of NPs had their physical characteristics (mean hydrodynamic diameter (Dz), polydispersity (P), mean zeta-potential (ζ), and conductance (G)) determined by dynamic light scattering (DSL), turbidimetry, and scanning electron microscopy (SEM). The content ofPMMA, PDDA, and DODAB in NPs also was characterized. PDDA, OVA, PDDA/OVA, PMMA/DODAB/PDDA, PMMA/DODAB, DODAB large vesicles (DODAB-LV), and DODAB bilayer fragment (DODAB-BF) toxicity was evaluated measuring cell viability against fibroblast and macrophages. Immunoadjuvant activity was assessed by determining antibody production (IgG1, IgG2a), delayed-type hypersensitivity reaction (DTH), and cytokines profile. PDDA/OVA (0.01/0.1 mg/mL) NPs displayed Dz=170±4 nm, ζ =+30±2 mV, and P=0.11±0.01. Free PDDA exhibited dose-dependent toxicity exerted by disrupting fibroblast membranes. PDDA/OVA NPs elicited a T helper 2 (Th2) immune response represented by high IgG1 production and DTH similar to Al(OH)3/OVA. On the other hand, PMMA/DODAB/PDDA NPs exhibited Dz=217±1 nm, ζ=+73±1 mV, and P=0.12±0.01. After 24h incubation, PMMA/DODAB/PDDA NPs at 0.05 mg/mL (used in mice immunization) were no toxic against fibroblast or macrophages. PMMA/DODAB/PDDA NPs elicited a dual Th1/Th2 immune response, IgG1 titers were four times higher than the titers quantified using Al(OH)3 as the adjuvant. DTH for PMMA/DODAB/PDDA NPs was significantly higher than the those registered for OVA or Al(OH)3/OVA. Th1/Th2 dual response for PMMA/DODAB/PDDA was confirmed by cytokines profile showing higher production of IFN-γ, IL-4, IL-2, and IL-10 than controls. NPs of PMMA/DODAB displayed Dz=80±1 nm, ζ=+52±3 mV, and P=0.07±0.01. PMMA/DODAB NPs were less toxic than DODAB-BF and DODAB-LV, both against fibroblast and macrophages, at the concentration used for immunizations. The immune response generated by PMMA/DODAB NPs was dual Th1/Th2, IgG1 titers were comparable to those elicited by Al(OH)3, IgG2a titers, as well as DTH, were significantly higher than the ones produced by OVA or Al(OH)3/OVA. Th1/Th2 dual response confirmation was attained by determining cytokines production, PMMA/DODABNPs generated both Th1 (IL-2, IFN-γ) and Th2 (IL-4) cytokines. In conslusion, obtained NPs were biocompatible, nanosized, showed high ζ and narrow particle size distribution. Cationic materials immobilization decreases their toxicity in vitro. NPs enhanced the immune response as compared with OVA and Al(OH)3/OVA. Bearing-PDDA NPs had a bias toward a Th2 type response with high titers of IgG1, while PMMA/DODAB NPs exhibited a dual Th1/Th2 response.
id USP_12a62404085e4f0cc3a219a4bc079aa5
oai_identifier_str oai:teses.usp.br:tde-23052022-152413
network_acronym_str USP
network_name_str Biblioteca Digital de Teses e Dissertações da USP
repository_id_str 2721
spelling Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activityNanopartículas poliméricas catiônicas e biocompatíveis: preparação, caracterização e atividade imunoadjuvanteAdjuvantes para vacinasArtigen carriersCarreadores de antígenosCationic lipidsCationic polymersInteração nanopartícula/proteínaLipídios catiônicosNanoparticlesNanoparticles/proteinNanopartículasPolímero/proteínaPolímeros catiônicosPolymer/protein interactionsVaccine adjuvantsVaccinesVacinasAdjuvants activate innate immunity by diverse mechanisms simulating the activity of danger signals present in entire pathogens but absent in purified antigens used in vaccines. Cationic nanoparticles (NPs) are promising adjuvants as they may show high colloidal stability, they adsorb oppositely charged antigens, and they increase antigens uptake by antigen-presenting cells (APC). The high toxicity displayed by isolated cationic lipids or polymers has hampered their use in vaccines. In this work, the toxicity of cationic materials is overcome by combining them with biocompatible polymers. Herein is described the preparation, characterization, toxicity, and immunoadjuvant activity of three cationic NPs, poly(diallyldimethylammchloride)/ovalbumin (PDDA/OVA), poly(methyl methacrylate)/dimethyldioctadecylammonium bromide/PDDA (PMMA/DODAB/PDDA), and PMMA/DODAB. NPs of PDDA/OVA were prepared by mixing PDDA and OVA; NPs of PMMA/DODAB/PDDA and PMMA/DODAB NPs were synthesized by emulsion polymerization of methyl methacrylate (MMA) in the presence of cationic components. Dispersion of NPs had their physical characteristics (mean hydrodynamic diameter (Dz), polydispersity (P), mean zeta-potential (ζ), and conductance (G)) determined by dynamic light scattering (DSL), turbidimetry, and scanning electron microscopy (SEM). The content ofPMMA, PDDA, and DODAB in NPs also was characterized. PDDA, OVA, PDDA/OVA, PMMA/DODAB/PDDA, PMMA/DODAB, DODAB large vesicles (DODAB-LV), and DODAB bilayer fragment (DODAB-BF) toxicity was evaluated measuring cell viability against fibroblast and macrophages. Immunoadjuvant activity was assessed by determining antibody production (IgG1, IgG2a), delayed-type hypersensitivity reaction (DTH), and cytokines profile. PDDA/OVA (0.01/0.1 mg/mL) NPs displayed Dz=170±4 nm, ζ =+30±2 mV, and P=0.11±0.01. Free PDDA exhibited dose-dependent toxicity exerted by disrupting fibroblast membranes. PDDA/OVA NPs elicited a T helper 2 (Th2) immune response represented by high IgG1 production and DTH similar to Al(OH)3/OVA. On the other hand, PMMA/DODAB/PDDA NPs exhibited Dz=217±1 nm, ζ=+73±1 mV, and P=0.12±0.01. After 24h incubation, PMMA/DODAB/PDDA NPs at 0.05 mg/mL (used in mice immunization) were no toxic against fibroblast or macrophages. PMMA/DODAB/PDDA NPs elicited a dual Th1/Th2 immune response, IgG1 titers were four times higher than the titers quantified using Al(OH)3 as the adjuvant. DTH for PMMA/DODAB/PDDA NPs was significantly higher than the those registered for OVA or Al(OH)3/OVA. Th1/Th2 dual response for PMMA/DODAB/PDDA was confirmed by cytokines profile showing higher production of IFN-γ, IL-4, IL-2, and IL-10 than controls. NPs of PMMA/DODAB displayed Dz=80±1 nm, ζ=+52±3 mV, and P=0.07±0.01. PMMA/DODAB NPs were less toxic than DODAB-BF and DODAB-LV, both against fibroblast and macrophages, at the concentration used for immunizations. The immune response generated by PMMA/DODAB NPs was dual Th1/Th2, IgG1 titers were comparable to those elicited by Al(OH)3, IgG2a titers, as well as DTH, were significantly higher than the ones produced by OVA or Al(OH)3/OVA. Th1/Th2 dual response confirmation was attained by determining cytokines production, PMMA/DODABNPs generated both Th1 (IL-2, IFN-γ) and Th2 (IL-4) cytokines. In conslusion, obtained NPs were biocompatible, nanosized, showed high ζ and narrow particle size distribution. Cationic materials immobilization decreases their toxicity in vitro. NPs enhanced the immune response as compared with OVA and Al(OH)3/OVA. Bearing-PDDA NPs had a bias toward a Th2 type response with high titers of IgG1, while PMMA/DODAB NPs exhibited a dual Th1/Th2 response.Os adjuvantes ativam a imunidade inata por diversos mecanismos que simulam a atividade dos sinais de perigo presentes em patógenos inteiros, mas ausentes em antígenos purificados. Nanopartículas (NPs) catiônicas são adjuvantes promissores, pois podem apresentar alta estabilidade coloidal, adsorver antígenos de carga oposta e aumentar a captação de antígenos pelas células apresentadoras de antígeno (APC). A alta toxicidade apresentada por lipídios ou polímeros catiônicos isolados tem dificultado seu uso em vacinas. Neste trabalho, a toxicidade de materiais catiônicos é superada combinando-os com polímeros biocompatíveis. É descrita a preparação, caracterização, toxicidade e atividade imunoadjuvante de três NPs catiônicas, cloreto de poli (dialildimetilamônio)/ovalbumina (PDDA/OVA), poli (metacrilato de metila)/brometo de dimetildioctadecilamônio/PDDA (PMMA/DODAB/PDMA) e PMMA/DODAB. NPs de PDDA/OVA foram preparadas misturando PDDA e OVA; NPs de PMMA/DODAB/PDDA e PMMA/DODAB foram sintetizados por polimerização em emulsão de metacrilato de metila (MMA) na presença dos componentes catiônicos. As dispersões de NPs tiveram suas características físicas (diâmetro hidrodinâmico médio (Dz), polidispersidade (P), potencial-zeta (ζ) e condutância (G)) determinadas por espalhamento de luz dinâmico (DSL), turbidimetria e microscopiaeletrônica de varredura (MEV). O conteúdo de PMMA, PDDA e DODAB em NPs também foi caracterizado. A toxicidade de PDDA, OVA, PDDA/OVA, PMMA/DODAB/PDDA, PMMA/DODAB, vesículas grandes de DODAB (DODAB-LV) e fragmento de bicamada de DODAB (DODAB-BF) foi avaliada medindo a viabilidade contra fibroblastos e macrófagos. A atividade imunoadjuvante foi avaliada pela determinação da produção de anticorpos (IgG1, IgG2a), reação de hipersensibilidade do tipo retardado (DTH) e perfil de citocinas. NPs de PDDA/OVA (0,01/0,1mg/mL) mostraram Dz=170±4nm, ζ=+30±2mV e P=0,11±0,01. PDDA livre exibiu toxicidade dependente da dose exercida pela ruptura das membranas dos fibroblastos. NPs de PDDA/OVA desencadearam uma resposta imune T helper-2 (Th2) representada por alta produção de IgG1 e DTH semelhante a Al(OH)3/OVA. NPs de PMMA/DODAB/PDDA exibiram Dz=217±1nm, ζ=+73±1mV e P=0,12±0,01. Após 24h de incubação, NPs de PMMA/DODAB/PDDA a 0,05mg/mL (usados na imunização) não foram tóxicas contra fibroblastos ou macrófagos. NPs de PMMA/DODAB/PDDA desencadearam uma resposta imune dual Th1/Th2, títulos de IgG1 foram quatro vezes maiores que os títulos quantificados usando Al(OH)3 como adjuvante. DTH para as NPs de PMMA/DODAB/PDDA foi significativamente maior que aqueles registrados para OVA ou Al(OH)3/OVA. A resposta dual Th1/Th2 para PMMA/DODAB/PDDA foi confirmada pelo perfil de citocinas mostrando maior produção de IFN-γ, IL-4, IL-2 e IL-10 que os controles. NPs de PMMA/DODAB exibiram Dz=80±1nm, ζ=+52±3mV e P=0,07±0,01 e foram menos tóxicas do que DODAB-BF e DODAB-LV, tanto contra fibroblastos quanto macrófagos. A resposta imune gerada por NPs de PMMA/DODAB foi dual Th1/Th2, títulos de IgG1 foram comparáveis aos eliciados por Al(OH)3, títulos de IgG2a, bem como DTH, foram significativamente maiores do que os produzidos por OVA ou Al(OH)3/OVA. A confirmação da resposta Th1/Th2 foi obtida através da determinação da produção de citocinas, NPs de PMMA/DODAB geraram citocinas Th1 (IL-2, IFN-γ) e Th2 (IL-4). Em conclusão, as NPs obtidas foram biocompatíveis, nanométricas, apresentaram ζ altos e distribuição de tamanho de partícula estreita. A imobilização de materiais catiônicos diminui sua toxicidade in vitro. NPs aumentaram a resposta imune comparado OVA e Al(OH) 3/OVA. NPs contendo PDDA induziram uma resposta Th2 com altos títulos de IgG1, enquanto NPs de PMMA/DODAB exibiram uma resposta dual Th1/Th2.Biblioteca Digitais de Teses e Dissertações da USPCarmona-Ribeiro, Ana Maria Pérez-Betancourt, Yunys Pérez2022-01-31info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/doctoralThesisapplication/pdfhttps://www.teses.usp.br/teses/disponiveis/46/46131/tde-23052022-152413/reponame:Biblioteca Digital de Teses e Dissertações da USPinstname:Universidade de São Paulo (USP)instacron:USPLiberar o conteúdo para acesso público.info:eu-repo/semantics/openAccesseng2022-05-24T15:57:29Zoai:teses.usp.br:tde-23052022-152413Biblioteca Digital de Teses e Dissertaçõeshttp://www.teses.usp.br/PUBhttp://www.teses.usp.br/cgi-bin/mtd2br.plvirginia@if.usp.br|| atendimento@aguia.usp.br||virginia@if.usp.bropendoar:27212022-05-24T15:57:29Biblioteca Digital de Teses e Dissertações da USP - Universidade de São Paulo (USP)false
dc.title.none.fl_str_mv Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
Nanopartículas poliméricas catiônicas e biocompatíveis: preparação, caracterização e atividade imunoadjuvante
title Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
spellingShingle Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
Pérez-Betancourt, Yunys Pérez
Adjuvantes para vacinas
Artigen carriers
Carreadores de antígenos
Cationic lipids
Cationic polymers
Interação nanopartícula/proteína
Lipídios catiônicos
Nanoparticles
Nanoparticles/protein
Nanopartículas
Polímero/proteína
Polímeros catiônicos
Polymer/protein interactions
Vaccine adjuvants
Vaccines
Vacinas
title_short Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
title_full Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
title_fullStr Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
title_full_unstemmed Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
title_sort Cationic and biocompatible polymeric nanoparticles: preparation, characterization, and immunoadjuvant activity
author Pérez-Betancourt, Yunys Pérez
author_facet Pérez-Betancourt, Yunys Pérez
author_role author
dc.contributor.none.fl_str_mv Carmona-Ribeiro, Ana Maria
dc.contributor.author.fl_str_mv Pérez-Betancourt, Yunys Pérez
dc.subject.por.fl_str_mv Adjuvantes para vacinas
Artigen carriers
Carreadores de antígenos
Cationic lipids
Cationic polymers
Interação nanopartícula/proteína
Lipídios catiônicos
Nanoparticles
Nanoparticles/protein
Nanopartículas
Polímero/proteína
Polímeros catiônicos
Polymer/protein interactions
Vaccine adjuvants
Vaccines
Vacinas
topic Adjuvantes para vacinas
Artigen carriers
Carreadores de antígenos
Cationic lipids
Cationic polymers
Interação nanopartícula/proteína
Lipídios catiônicos
Nanoparticles
Nanoparticles/protein
Nanopartículas
Polímero/proteína
Polímeros catiônicos
Polymer/protein interactions
Vaccine adjuvants
Vaccines
Vacinas
description Adjuvants activate innate immunity by diverse mechanisms simulating the activity of danger signals present in entire pathogens but absent in purified antigens used in vaccines. Cationic nanoparticles (NPs) are promising adjuvants as they may show high colloidal stability, they adsorb oppositely charged antigens, and they increase antigens uptake by antigen-presenting cells (APC). The high toxicity displayed by isolated cationic lipids or polymers has hampered their use in vaccines. In this work, the toxicity of cationic materials is overcome by combining them with biocompatible polymers. Herein is described the preparation, characterization, toxicity, and immunoadjuvant activity of three cationic NPs, poly(diallyldimethylammchloride)/ovalbumin (PDDA/OVA), poly(methyl methacrylate)/dimethyldioctadecylammonium bromide/PDDA (PMMA/DODAB/PDDA), and PMMA/DODAB. NPs of PDDA/OVA were prepared by mixing PDDA and OVA; NPs of PMMA/DODAB/PDDA and PMMA/DODAB NPs were synthesized by emulsion polymerization of methyl methacrylate (MMA) in the presence of cationic components. Dispersion of NPs had their physical characteristics (mean hydrodynamic diameter (Dz), polydispersity (P), mean zeta-potential (ζ), and conductance (G)) determined by dynamic light scattering (DSL), turbidimetry, and scanning electron microscopy (SEM). The content ofPMMA, PDDA, and DODAB in NPs also was characterized. PDDA, OVA, PDDA/OVA, PMMA/DODAB/PDDA, PMMA/DODAB, DODAB large vesicles (DODAB-LV), and DODAB bilayer fragment (DODAB-BF) toxicity was evaluated measuring cell viability against fibroblast and macrophages. Immunoadjuvant activity was assessed by determining antibody production (IgG1, IgG2a), delayed-type hypersensitivity reaction (DTH), and cytokines profile. PDDA/OVA (0.01/0.1 mg/mL) NPs displayed Dz=170±4 nm, ζ =+30±2 mV, and P=0.11±0.01. Free PDDA exhibited dose-dependent toxicity exerted by disrupting fibroblast membranes. PDDA/OVA NPs elicited a T helper 2 (Th2) immune response represented by high IgG1 production and DTH similar to Al(OH)3/OVA. On the other hand, PMMA/DODAB/PDDA NPs exhibited Dz=217±1 nm, ζ=+73±1 mV, and P=0.12±0.01. After 24h incubation, PMMA/DODAB/PDDA NPs at 0.05 mg/mL (used in mice immunization) were no toxic against fibroblast or macrophages. PMMA/DODAB/PDDA NPs elicited a dual Th1/Th2 immune response, IgG1 titers were four times higher than the titers quantified using Al(OH)3 as the adjuvant. DTH for PMMA/DODAB/PDDA NPs was significantly higher than the those registered for OVA or Al(OH)3/OVA. Th1/Th2 dual response for PMMA/DODAB/PDDA was confirmed by cytokines profile showing higher production of IFN-γ, IL-4, IL-2, and IL-10 than controls. NPs of PMMA/DODAB displayed Dz=80±1 nm, ζ=+52±3 mV, and P=0.07±0.01. PMMA/DODAB NPs were less toxic than DODAB-BF and DODAB-LV, both against fibroblast and macrophages, at the concentration used for immunizations. The immune response generated by PMMA/DODAB NPs was dual Th1/Th2, IgG1 titers were comparable to those elicited by Al(OH)3, IgG2a titers, as well as DTH, were significantly higher than the ones produced by OVA or Al(OH)3/OVA. Th1/Th2 dual response confirmation was attained by determining cytokines production, PMMA/DODABNPs generated both Th1 (IL-2, IFN-γ) and Th2 (IL-4) cytokines. In conslusion, obtained NPs were biocompatible, nanosized, showed high ζ and narrow particle size distribution. Cationic materials immobilization decreases their toxicity in vitro. NPs enhanced the immune response as compared with OVA and Al(OH)3/OVA. Bearing-PDDA NPs had a bias toward a Th2 type response with high titers of IgG1, while PMMA/DODAB NPs exhibited a dual Th1/Th2 response.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-31
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/doctoralThesis
format doctoralThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://www.teses.usp.br/teses/disponiveis/46/46131/tde-23052022-152413/
url https://www.teses.usp.br/teses/disponiveis/46/46131/tde-23052022-152413/
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv
dc.rights.driver.fl_str_mv Liberar o conteúdo para acesso público.
info:eu-repo/semantics/openAccess
rights_invalid_str_mv Liberar o conteúdo para acesso público.
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.coverage.none.fl_str_mv
dc.publisher.none.fl_str_mv Biblioteca Digitais de Teses e Dissertações da USP
publisher.none.fl_str_mv Biblioteca Digitais de Teses e Dissertações da USP
dc.source.none.fl_str_mv
reponame:Biblioteca Digital de Teses e Dissertações da USP
instname:Universidade de São Paulo (USP)
instacron:USP
instname_str Universidade de São Paulo (USP)
instacron_str USP
institution USP
reponame_str Biblioteca Digital de Teses e Dissertações da USP
collection Biblioteca Digital de Teses e Dissertações da USP
repository.name.fl_str_mv Biblioteca Digital de Teses e Dissertações da USP - Universidade de São Paulo (USP)
repository.mail.fl_str_mv virginia@if.usp.br|| atendimento@aguia.usp.br||virginia@if.usp.br
_version_ 1809091015324205056